Pfizer tests how experimental drug PF-07976016 travels in the body
NCT ID NCT07015918
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how the experimental drug PF-07976016 is absorbed, distributed, and removed from the body. Eight healthy male volunteers took the drug by mouth and by vein so researchers could track its path using a tiny radioactive marker. The goal was purely to understand the drug's behavior, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- PF-07976016
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
8 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Aug 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Males, 18 to 65 years of age * BMI 17.5 to 32 kg/m2 and a total body weight \>50 kg (110 lb) * Willing and able to comply with all study procedures Exclusion Criteria: * History of irregular bowel movements or lactose intolerance * Any medical or psychiatric condition or laboratory abnormality or other condition that may increase the risk of study participation * Use of any prohibited or concomitant medication(s) * Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests * Positive urine drug test * History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence * Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day * Previous administration of an investigational product within 30 days preceding the first dose of study medicine in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy male volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON
Groningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.